The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer

We investigated the correlation of vascular endothelial growth factor C, matrix metalloproteinase-2, E-cadherin to explore mechanisms of vascular endothelial growth factor C in the metastasis of ovarian cancer and the relationship of prognosis. We applied immunohistochemistry to investigate the expression of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in ovarian tissues of 227 patients. We adopted Pearson chi-square test, Spearman correlation coefficient, univariate analysis, multivariate analysis, and Kaplan–Meier method. The positive rate of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in ovarian cancer was higher than that in borderline and benign tumor (P < 0.01). Vascular endothelial growth factor C was positively correlated with matrix metalloproteinase-2 (r = 0.665, P < 0.01) while negatively with E-cadherin(r = −0.185, P < 0.05). Univariate analysis showed clinical stage, pathologic grade, lymphatic metastasis, residual disease, chemotherapy, ascites, vascular endothelial growth factor C, and matrix metalloproteinase-2-influenced survival time (P < 0.05). In Cox multivariate analysis, all the aforementioned factors were found to be independent prognostic factors except pathologic grade. Vascular endothelial growth factor C was a new target to assess the prognosis of ovarian cancer. The expression of vascular endothelial growth factor C in ovarian cancer was related to matrix metalloproteinase-2 and E-cadherin.

[1]  M. Swartz,et al.  Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. , 2009, Cancer research.

[2]  P. Torng,et al.  Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. , 2004, Gynecologic oncology.

[3]  Zuojie Luo,et al.  Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis. , 2010, The International journal of biological markers.

[4]  Hsin-Yi Huang,et al.  Co-Expression of VEGF-C and Its Receptors, VEGFR-2 and VEGFR-3, in Endothelial Cells of Lymphangioma. Implication in Autocrine or Paracrine Regulation of Lymphangioma , 2001, Laboratory Investigation.

[5]  Y. Kuroda,et al.  Frequent Occurrence of Abnormal E-Cadherin/β-Catenin Protein Expression in Advanced Gallbladder Cancers and Its Association with Decreased Apoptosis , 2007, Oncology.

[6]  A. Ayhan,et al.  Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects , 2006, International Journal of Gynecologic Cancer.

[7]  D. Dinh,et al.  Downregulation of matrix metalloproteinase-2 (MMP-2) utilizing adenovirus-mediated transfer of small interfering RNA (siRNA) in a novel spinal metastatic melanoma model. , 2008, International journal of oncology.

[8]  D. Bates,et al.  Vascular endothelial growth factor-C, a potential paracrine regulator of glomerular permeability, increases glomerular endothelial cell monolayer integrity and intracellular calcium. , 2008, The American journal of pathology.

[9]  S. Curran,et al.  Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. , 2000, European journal of cancer.

[10]  Jeffrey Bell,et al.  Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. , 2006, Gynecologic oncology.

[11]  M. Waltham,et al.  Pro-Matrix Metalloproteinase-2 Transfection Increases Orthotopic Primary Growth and Experimental Metastasis of MDA-MB-231 Human Breast Cancer Cells in Nude Mice , 2004, Cancer Research.

[12]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[13]  I. Abdelazim,et al.  Immunoexpression of matrix metalloproteinase-2 (MMP-2) in malignant ovarian epithelial tumours. , 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

[14]  M. Hung,et al.  The role of the VEGF-C/VEGFR-3 axis in cancer progression , 2006, British Journal of Cancer.

[15]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[16]  M. Dimopoulos,et al.  Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  Overexpression of Lymphangiogenic Growth Factor VEGF-C in Human Pancreatic Cancer , 2001, Pancreas.

[18]  Y. Hung,et al.  Vascular Endothelial Growth Factor-C Expression and Invasive Phenotype in Ovarian Carcinomas , 2005, Clinical Cancer Research.

[19]  N. Sakuragi,et al.  Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). , 2000, Gynecologic oncology.

[20]  K. Hirakawa,et al.  Association between Expression of Vascular Endothelial Growth Factor C, Chemokine Receptor CXCR4 and Lymph Node Metastasis in Colorectal Cancer , 2007, Oncology.